Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?

Thrombosis Research

Volumn 120, Issue 4, 2007, Pages 549-558

  Bird, Eileen ^a   Tamura, James ^a   Bostwick, Jeffrey S ^a   Steinbacher, Thomas E ^a   Stewart, Anne ^a   Liu, Yizhi ^a   Baumann, Jergen ^a   Feyen, Jean ^a   Tamasi, Joseph ^a   Schumacher, William A ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Bleeding time; Carboxypeptidase; Thrombelastograph; Tissue factor

Indexed keywords

FERROUS CHLORIDE; POTATO CARBOXYPEPTIDASE INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOVENOUS SHUNT; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; KIDNEY; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE; THROMBOELASTOGRAPHY; VEIN THROMBOSIS;

ANIMALS; CARBOXYPEPTIDASE U; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; HEMORRHAGE; MALE; PLANT PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34447644598     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.11.010     Document Type: Article

References (20)

1. Wang W., Boffa M.B., Bajzar L., Walker J.B., and Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin activatable fibrinolysis inhibitor. J Biol Chem 273 (1998) 27176-27181
2. Suzuki K., Muto Y., Fushihara K., Kanemoto K.-K., Lida H., Sato E., et al. Enhancement of fibrinolysis by EF6265 [(S)-7amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl] heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 309 (2004) 607-615
3. Hashimoto M., Yamashita T., Oiwa K., Watanabe S., Giddings J.C., and Yamamoto J. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles. Thromb Haemost 87 (2002) 110-113
4. Wang X., Smith P.L., Hsu M.-Y., Ogletree M., and Schumacher W.A. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Hemost 4 (2006) 403-410
5. Nagashima M., Yin Z.F., Zhao L., White K., Zhu Y., Lasky N., et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 109 (2002) 101-110
6. Nagashima M., Werner M., Wang M., Zhao L., Light D.R., Pagila R., et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 98 (2000) 333-342
7. Refino C.J., DeGuzman L., Schmitt D., Smyth R., Jeet S., Lipari M.T., et al. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis, and hemostasis. Fibrinolysis Proteolysis 14 (2000) 305-314
8. Mosnier L.O., Elisen M.G.L.M., Bouma B.N., and Meijers J.C.M. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down-regulation of TAFI activation. Thromb Haemost 86 (2001) 1057-1064
9. Colucci M., D'Aprile A.M., Italia A., Gresele P., Morser J., and Semeraro N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 85 (2001) 661-666
10. Padro T., Quax P.H., van den Hoogen C.M., Roholl P., Verheijen J.H., and Emeis J.J. Tissue-type plasminogen activator and its inhibitor in rat aorta: effect of endotoxin. Arterioscler Thromb 14 (1994) 1459-1465
11. Paloma M.J., Paramo J.A., and Rocha E. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator on PAI-1 generation, fibrin deposits and mortality. Thromb Haemost 74 (1995) 1578-1582
12. Klement P., Liao P., and Bajzar L. A novel approach to arterial thrombolysis. Blood 94 (1999) 2735-2743
13. Schumacher W.A., Steinbacher T.E., and Heran C.L. Low molecular weight heparin (fragmin) and thrombin active site inhibitor (argatroban) compared in experimental venous and arterial thrombosis and bleeding time. J Cardiovasc Pharmacol 28 (1996) 19-25
14. Das J., Kimball S., Hall S.E., Han W., Iwanowicz E., Lin J., et al. Molecular design and structure-activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. Bioorg Med Chem Lett 12 (2002) 45-49
15. Schatteman K.A., Goossens J.J., Scharpe S.S., and Hendricks D.F. Activation of plasma carboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis. Thromb Haemost 82 (1999) 1718-1721
16. Park C.-Y., Jung S.-H., Bak J.-P., Lee S.-S., and Rhee D.-K. Comparison of the rabbit pyrogen test and Limilus amoebocyte lysate (LAL) assay for endotoxin in hepatitis B vaccines and the effect of aluminum hydroxide. Biologicals 33 (2005) 145-151
17. Xing H.C., Li L.J., Xu K.J., Shen T., Chen Y.B., Chen Y., et al. Effects of Salvia miltiorrhiza on intestinal microflora in rats with ischemia/reperfusion liver injury. Hepatobiliary Pancreat Dis Int 4 (2005) 274-280
18. Schneider M., and Nesheim M. Reversible inhibitors of TAFI can both promote and inhibit fibrinolysis. J Thromb Haemostas 1 (2003) 147-154
19. Walker J.B., Hughes B., James I., Haddock P., Kluft C., and Bajzar L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 278 (2003) 8913-8921
20. Muto Y., Suzuki K., Sato E., and Ishii H. Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 461 (2003) 181-189